Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Podcast 24: The Pipeline Contenders: What Drugs Are Making the Mark?

In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential.

Key topics: (see Chapter Markers)

  • Inside Big Pharma’s pipeline
  • AbbVie
  • Amgen/AstraZeneca
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Roche

Sponsor: Vetter Pharma International GmbH

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Podcast 44: What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights…

Podcast 43: CDMOs/CMOs: The Movers and Shakers of 2023

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the…

Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an…

Podcast 41: API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains 

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages…